Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Pliant Therapeutics Inc
(NQ:
PLRX
)
13.80
UNCHANGED
Streaming Delayed Price
Updated: 1:00 PM EST, Nov 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pliant Therapeutics Inc
< Previous
1
2
3
4
5
6
7
Next >
IPF Has A 0% Survival Rate Without Lung Transplant And A Median Survival Time Of 2-5 Years From Diagnosis – Could GRI-0621 Be The Solution?
August 31, 2023
Idiopathic Pulmonary Fibrosis (IPF) is a serious chronic lung disease characterized by the thickening and stiffening of the lung tissue surrounding the air sacs. The exact cause of IPF is unknown, but...
Via
Benzinga
Pliant Therapeutics to Participate in Upcoming Investor Conferences
August 30, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023
August 28, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Where Pliant Therapeutics Stands With Analysts
August 22, 2023
Via
Benzinga
Expert Ratings for Pliant Therapeutics
May 18, 2023
Via
Benzinga
Recap: Pliant Therapeutics Q1 Earnings
May 09, 2023
Via
Benzinga
What 12 Analyst Ratings Have To Say About Pliant Therapeutics
May 02, 2023
Via
Benzinga
Pliant Therapeutics Shares Fall After Long-Term Data Of Bexotegrast In Lung Fibrosis Study
May 01, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
August 17, 2023
Via
Benzinga
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 09, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis
August 09, 2023
Follows positive data from INTEGRIS-IPF Phase 2a trial
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Conferences
July 25, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Expert Ratings for Pliant Therapeutics
April 13, 2023
Via
Benzinga
The Latest Analyst Ratings for Pliant Therapeutics
March 28, 2023
Via
Benzinga
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
June 23, 2023
Presentations highlight preclinical and clinical advancements of bexotegrast program in primary sclerosing cholangitis
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
May 24, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
May 18, 2023
Via
Benzinga
Pliant Therapeutics to Participate in Upcoming Investor Events
May 10, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 09, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
May 01, 2023
Via
Benzinga
First Republic Bank, Top Financial And Other Big Stocks Moving Lower On Monday
May 01, 2023
U.S. stocks traded lower, with the Nasdaq falling around 17 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
US Stocks Rise; Norwegian Cruise Line Posts Q1 Results
May 01, 2023
U.S. stocks traded higher this morning, ahead of the Federal Reserve’s monetary policy meeting. Following the market opening Monday, the Dow traded up 0.15% to 34,147.97, while the NASDAQ inched up...
Via
Benzinga
Why First Republic Bank Shares Are Trading Lower By 34%; Here Are 20 Stocks Moving Premarket
May 01, 2023
Gainers Hongli Group Inc. (NASDAQ: HLP) gained 317.8% to $17.55 in pre-market trading. Hongli Group recently announced pricing of $8.25 million initial public offering of 2,062,500 ordinary shares at a...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 01, 2023
Via
Benzinga
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures
April 30, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023
April 13, 2023
Via
Benzinga
Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference
April 12, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
7 Biotech Stocks to Buy for 100% Returns
April 09, 2023
If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio.
Via
InvestorPlace
Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference
March 27, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
March 13, 2023
Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-PSC Phase 2a trial continue without modification and proceed to evaluate 320 mg dose
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.